NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP
Biodesix Inc. BDSX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$88.5M
▲ 24.1% vs FY2024
EPS · FY25
$-4.67
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-383.1%
Net margin · FY25
-39.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 88.5M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
USD -4.67
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-383.1%
Return on equity, FY2025
ROE
Operating margin-31.5%
Net margin-39.8%
Return on assets-38.2%
Each USD of equity lost 383 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+32.3%
+14.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 87.5M
total assets, end of FY2025
Total assetsUSD 87.5M
EquityUSD -2.5M
CashUSD 19.0M
Gross debtUSD 50.0M
Net debtUSD 31.0M
Current ratio1.86×
Net debt stands at -1258% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.1
0.0
0.0
0.1
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
EPS, diluted $
−4.67
−6.64
−0.64
−1.55
−1.58
−6.48
−126.97
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−383.1
−337.3
−414.1
−324.5
−141.8
·
·
Shares out B
0.01
0.01
0.10
0.08
0.03
0.03
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed